文献速递产科

剖宫产子宫切口头尾方向钝性扩张优于横向扩张:一项荟萃分析

Cephalad-caudad versus transverse blunt expansion of the low transverse hysterotomy during cesarean delivery decreases maternal morbidity: a meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-21

该荟萃分析纳入随机对照试验,比较剖宫产低横切口头尾方向钝性扩张与横向钝性扩张对母婴结局的影响。结果显示头尾方向扩张可降低非预期切口延裂和子宫血管损伤风险,且不增加额外缝合或输血需求,手术时间无差异。

要点

  • 头尾方向钝性扩张降低非预期切口延裂风险(RR 0.62,95%CI 0.45-0.86)。
  • 头尾方向扩张降低子宫血管损伤风险(RR 0.55,95%CI 0.41-0.73)。
  • 两种扩张方式在额外缝合、输血率及手术时间上无显著差异。

核心结论

  • 剖宫产子宫切口头尾方向钝性扩张在减少非预期切口延裂和子宫血管损伤方面优于横向扩张。

研究设计与样本

  • 系统检索Medline、Scopus、Cochrane对照试验中心注册库、Google Scholar和ClinicalTrials.gov从建库至2021年1月的随机对照试验。
  • 采用Hartung-Knapp-Sidik-Jonkman随机效应模型计算效应量,并进行了试验序贯分析。

主要发现

  • 头尾方向扩张组非预期切口延裂发生率更低(RR 0.62,95%CI 0.45-0.86)。
  • 头尾方向扩张组子宫血管损伤发生率更低(RR 0.55,95%CI 0.41-0.73)。
  • 两组额外缝合需求(RR 0.62,95%CI 0.31-4.12)和输血率(RR 0.75,95%CI 0.28-2.03)无显著差异。
  • 两组手术时间无显著差异(均数差 -0.45分钟,95%CI -2.12至1.21)。
  • 两组倒T形切口延裂风险无显著差异(RR 0.38,95%CI 0.09-1.52)。

关键数值与推荐

  • 非预期切口延裂:RR 0.62(95%CI 0.45-0.86)。
  • 子宫血管损伤:RR 0.55(95%CI 0.41-0.73)。
  • 额外缝合需求:RR 0.62(95%CI 0.31-4.12)。
  • 输血率:RR 0.75(95%CI 0.28-2.03)。
  • 手术时间均数差:-0.45分钟(95%CI -2.12至1.21)。

临床怎么用

  • 剖宫产低横切口可采用头尾方向钝性扩张以减少切口延裂和血管损伤。

局限性

  • 试验序贯分析仅显示非预期切口延裂和子宫血管损伤结局达到所需样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cesarean delivery is the most prevalent surgical procedure worldwide, reaching approximately 29.7 million cases in 2015. It is directly associated with an increased risk of maternal and neonatal morbidity rates in the absence of malpresentation. Several techniques have been investigated, and there is evidence that cephalad-caudad expansion of the uterine incision might be associated with improved maternal outcomes compared with traditional transverse blunt expansion. The purpose of this meta-analysis was to evaluate the impact of cephalad-caudad expansion on adverse maternal outcomes, including intraoperative blood loss, risk of uterine vessel injury, and tearing of the lower uterine segment. DATA SOURCES: We searched Medline, Scopus, the Cochrane Central Register of Controlled Trials, Google Scholar, and Clinicaltrials.gov databases from inception to January 2021. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials that assessed the impact of the cephalad-caudad blunt expansion of the low transverse uterine incision during cesarean delivery rather than those of transverse blunt expansion were selected for inclusion. METHODS: Effect sizes were calculated with the Hartung-Knapp-Sidik-Jonkman random-effects model in R. Trial sequential analysis was performed to evaluate the adequacy of sample sizes. RESULTS: Cephalad-caudad blunt expansion of the uterine incision was associated with a lower prevalence of unintended incision extension (relative risk, 0.62; 95% confidence interval, 0.45-0.86) and uterine vessel injury (relative risk, 0.55; 95% confidence interval 0.41-0.73). However, these complications were not accompanied by the increased need for additional suture placement (relative risk, 0.62; 95% confidence interval, 0.31-4.12) or transfusion rates (relative risk, 0.75; 95% confidence interval, 0.28-2.03). Similarly, the intraoperative duration was comparable with cases treated with transverse blunt expansion (mean difference = -0.45 minutes; 95% confidence interval -2.12 to 1.21) and the risk of intentional incision extension in the form of an inverted T (relative risk, 0.38; 95% confidence interval, 0.09-1.52). Trial sequential analysis revealed that the required sample size was reached in the unintended incision extension and uterine vessel injury outcomes. CONCLUSION: The findings of our study suggested that cephalad-caudad blunt expansion of the uterine incision is superior to transverse expansion in terms of reducing unintended incision extension and uterine vessel injury.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pergialiotis V, Mitsopoulou D, Biliou E, et al. Cephalad-caudad versus transverse blunt expansion of the low transverse hysterotomy during cesarean delivery decreases maternal morbidity: a meta-analysis. Am J Obstet Gynecol. 2021. PMID: 33894151. doi:10.1016/j.ajog.2021.04.231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。